Loading...
•
Jun 30, 2024
Soleno Therapeutics Q2 2024 Earnings Report
Soleno Therapeutics reported financial results for Q2 2024 and provided a corporate update.
Key Takeaways
Soleno Therapeutics reported a net loss of $21.9 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $294.6 million as of June 30, 2024. Research and development expenses increased to $12.3 million, and general and administrative expenses rose to $10.9 million.
Submitted New Drug Application (NDA) to the FDA for Diazoxide Choline Extended-Release (DCCR) for the treatment of Prader-Willi Syndrome (PWS).
Closed an approximately $158.7 million underwritten public offering.
Granted Breakthrough Therapy Designation by the FDA for DCCR for the treatment of adults and children ages four years and older with genetically confirmed PWS who have hyperphagia.
Joined the broad-market Russell 3000® Index effective July 1, 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...